CRADD Antibody

What is CRADD and what cellular mechanisms is it involved in?

CRADD (Caspase and RIP adapter with death domain) is a 22kDa widely-expressed cytosolic adaptor/signaling protein that functions as a critical mediator of cell apoptosis in numerous tissues. It contains a death domain (CARD/DD) that recruits caspase 2/ICH1 to the cell death signal transduction complex including tumor necrosis factor receptor 1 (TNFR1A), RIPK1/RIP kinase, and other CARD domain-containing proteins . CRADD constitutes a vital component in the apoptotic signaling pathway, facilitating the transmission of death signals through its structural domains. The protein is also known by several synonyms including RAIDD, MGC9163, and MRT34, which reflect its various functional characterizations in scientific literature .

What types of CRADD antibodies are available for research applications?

Several types of CRADD antibodies have been developed for research purposes, each with specific characteristics suitable for different experimental applications:

These antibodies are specifically designed for laboratory research use only and should not be used for diagnostic, therapeutic, or other clinical applications .

What are the optimal sample preparation methods for CRADD antibody applications?

When preparing samples for CRADD antibody applications, researchers should consider the specific cellular localization of CRADD as a cytosolic protein. For Western blot applications, total cell lysates from model cell lines such as MCF7 have been successfully used with CRADD antibodies at concentrations of approximately 2 μg/mL, detecting a characteristic 22 kDa band . For immunohistochemistry, human kidney tissue samples have shown good results with antibody concentrations starting at 10 μg/mL . Sample preparation should include proper fixation protocols depending on the application; for immunofluorescence studies in cell lines like HeLa, antibody concentrations of approximately 20 μg/mL have been effective . It is critical to avoid freeze-thaw cycles when working with antibody solutions to maintain optimal reactivity and specificity in all applications .

How does CRADD interact with other proteins in apoptotic pathways?

CRADD functions as a critical adaptor protein in apoptotic pathways through multiple protein-protein interactions. Through its CARD domain, CRADD directly interacts with and recruits caspase-2 (formerly known as ICH1) to the cell death signal transduction complex . Simultaneously, its death domain (DD) facilitates interaction with receptor-interacting protein kinase 1 (RIPK1/RIP) . This dual-domain structure allows CRADD to serve as a molecular bridge in the formation of death-inducing signaling complexes.

Research indicates that CRADD participates in several signaling pathways:

• TNF-alpha/NF-kB Signaling Pathway

• Caspase Cascade in Apoptosis Pathway

• Ceramide Signaling Pathway

• Apoptosis Modulation and Signaling Pathway

Publications have documented significant interactions between CRADD and several key proteins, including CASP8 (>11 publications), CASP2 (>10 publications), FADD (>9 publications), RIPK1 (>6 publications), LRDD (>6 publications), and TRADD (>3 publications) . These interactions form a complex network essential for controlled cellular apoptosis and tissue homeostasis.

What experimental considerations are important when studying CRADD in endothelial cell homeostasis?

When investigating CRADD's role in endothelial cell homeostasis, researchers should implement multi-faceted experimental approaches to generate comprehensive data. Based on published methodologies, three complementary approaches have proven effective: (i) reduction of CRADD expression in murine endothelial cells using shRNA techniques, (ii) analysis of microvascular endothelial cells isolated from CRADD-deficient mice, and (iii) intracellular delivery of recombinant cell-penetrating CRADD protein homologs (CP-CRADD) to both CRADD-deficient and sufficient endothelial cells .

For studies focusing on endothelial barrier function, primary lung microvascular endothelial cells (LMEC) provide an appropriate model system. When designing permeability assays, researchers should carefully select appropriate agonists that induce barrier dysfunction and establish robust quantification methods. The experimental design should include appropriate controls, including CRADD-sufficient cells subjected to identical conditions, to isolate CRADD-specific effects from general cellular responses .

Temporal considerations are crucial when studying CRADD in endothelial homeostasis; researchers should conduct time-course experiments to distinguish between acute and chronic effects of CRADD deficiency or augmentation. Additionally, investigators should consider the CRADD-BCL10 axis as a potential mediator of anti-inflammatory effects in endothelial cells when designing experiments and interpreting results .

How can computational tools be integrated into CRADD antibody research?

Integrating computational tools into CRADD antibody research can significantly enhance experimental design and data interpretation. Recent advances in computational antibody design frameworks, such as RosettaAntibodyDesign (RAbD), offer powerful approaches for antibody engineering and optimization. When applying these tools to CRADD antibody research, researchers should consider several methodological aspects.

The RAbD framework samples antibody sequences and structures by grafting structures from canonical clusters of CDRs (Complementarity-Determining Regions), then performs sequence design according to amino acid profiles of each cluster . For CRADD antibody research, this approach can be valuable for designing antibodies with enhanced specificity or affinity for specific epitopes of the CRADD protein.

When implementing computational approaches, researchers should:

• Start with existing experimental or computationally modeled CRADD-antibody structures

• Apply strategies that optimize either total Rosetta energy or interface energy alone

• Utilize metrics such as Design Risk Ratio (DRR) and Antigen Risk Ratio (ARR) to evaluate success

• Consider CDR grafting approaches for CDR optimization

Experimental validation remains crucial; successful computational antibody design should be verified through binding assays demonstrating improved affinities. Published studies have achieved 10 to 50-fold improvements in antibody affinities through CDR replacement guided by computational design .

What approaches can address contradictory data in CRADD-related inflammation research?

When confronting contradictory data in CRADD-related inflammation research, a systematic analysis framework is essential. The apparently paradoxical observation of a CRADD-BCL10 anti-inflammatory axis requires careful experimental design and interpretation . To reconcile conflicting data, researchers should:

• Evaluate cellular context specificity: Determine whether contradictory results stem from cell type-specific effects by conducting parallel experiments in multiple relevant cell types (immune cells versus endothelial cells).

• Examine pathway cross-talk: Investigate potential cross-talk between CRADD-mediated apoptotic pathways and inflammatory signaling cascades. This requires simultaneous measurement of multiple endpoints across both pathways.

• Consider protein isoforms and post-translational modifications: Analyze whether specific CRADD isoforms or post-translational modifications might explain divergent functional outcomes.

• Apply time-resolved approaches: Implement time-course experiments to distinguish between early and late effects of CRADD activation or inhibition on inflammatory processes.

• Leverage genetic models with controls: When using CRADD-deficient models, include comprehensive controls and rescue experiments with recombinant CRADD to confirm specificity.

A methodical approach that systematically tests each potential source of contradiction will provide clarity in reconciling apparently conflicting data about CRADD's role in inflammation. Researchers should also consider whether the anti-inflammatory CRADD-BCL10 axis operates independently from or in conjunction with CRADD's established role in apoptotic signaling .

How should researchers interpret variations in CRADD antibody reactivity across different experimental systems?

Variations in CRADD antibody reactivity across different experimental systems represent a significant challenge in research interpretation. These variations may stem from multiple factors that researchers must systematically evaluate:

When encountering reactivity variations, researchers should implement a systematic validation protocol. For Western blot applications, this includes side-by-side comparison of multiple antibodies targeting different CRADD epitopes to confirm band specificity . For immunohistochemistry and immunofluorescence applications, validation through CRADD knockdown or knockout controls is essential to confirm signal specificity .

Additionally, researchers should consider that recommended starting dilutions (e.g., 1:500) are guidelines that require optimization for each specific experimental system . Titration experiments should be conducted to determine the optimal antibody concentration that maximizes specific signal while minimizing background for each application and sample type.

What are the optimal storage and handling protocols for maintaining CRADD antibody activity?

Proper storage and handling of CRADD antibodies is crucial for maintaining their activity and specificity over time. Based on manufacturer recommendations, CRADD antibodies should be stored according to the following protocol:

• Short-term storage (up to 1 month): Store at 4°C in the provided buffer systems.

• Long-term storage: Store at -20°C, where stability has been demonstrated for up to 12 months .

• Critical precaution: Prevent freeze-thaw cycles, which can significantly degrade antibody quality .

For formulated CRADD antibodies, typical buffer systems include PBS (pH 7.4) with stabilizers such as 10% glycerol and preservatives like 0.02% sodium azide . When working with the antibody, researchers should aliquot the stock solution upon first thawing to minimize freeze-thaw cycles for the main stock.

Before applying CRADD antibodies in experiments, temperature equilibration is recommended—allow refrigerated antibodies to reach room temperature gradually before opening the container to prevent condensation that could introduce contaminants. For diluted working solutions, prepare fresh on the day of use for optimal performance, particularly for sensitive applications like immunohistochemistry or immunofluorescence .

What optimization strategies should be employed for Western blot analysis using CRADD antibodies?

Optimizing Western blot protocols for CRADD antibody applications requires systematic adjustment of several experimental parameters. Based on published methodologies, researchers should follow these optimization strategies:

• Sample preparation: Total cell lysates from appropriate cell lines (such as MCF7) have been successfully used for CRADD detection . Ensure complete protein denaturation through proper sample buffer composition and heating.

• Loading control selection: When examining CRADD expression levels, select appropriate housekeeping proteins as loading controls based on the cellular compartment being studied (cytosolic).

• Antibody dilution optimization: While recommended starting dilutions of 1:500 are suggested , researchers should perform a dilution series (e.g., 1:250, 1:500, 1:1000) to determine optimal signal-to-noise ratio for their specific experimental conditions.

• Transfer optimization: Due to the relatively small size of CRADD (22 kDa), use transfer conditions optimized for small proteins, such as shorter transfer times or specialized transfer buffers containing methanol.

• Blocking optimization: Test multiple blocking agents (BSA vs. non-fat milk) as some antibodies perform differently depending on the blocking agent used.

• Signal detection: For CRADD with moderate expression levels, enhanced chemiluminescence systems with higher sensitivity may be required; consider testing multiple exposure times to capture optimal signal.

When troubleshooting, recognize that CRADD appears as a distinct 22 kDa band on Western blots . Non-specific bands or altered mobility could indicate post-translational modifications or protein complexes that require further investigation.

What considerations are important when using CRADD antibodies in immunohistochemistry applications?

When employing CRADD antibodies for immunohistochemistry (IHC) applications, researchers must consider several methodological factors to obtain reliable and reproducible results:

• Tissue fixation protocol: The choice between formalin-fixed paraffin-embedded (FFPE) and frozen sections can significantly impact epitope accessibility. For CRADD detection, both methods have been successfully employed, but optimization for each specific antibody is recommended.

• Antigen retrieval methods: For FFPE sections, heat-induced epitope retrieval (HIER) methods should be systematically tested, comparing citrate buffer (pH 6.0) versus EDTA buffer (pH 9.0) to determine optimal epitope exposure.

• Antibody concentration: Begin with the recommended concentration of 10 μg/mL for IHC applications , but perform a concentration gradient to determine optimal signal-to-background ratio for each specific tissue type.

• Detection system selection: For tissues with lower CRADD expression levels, amplification systems such as polymer-based detection methods may provide superior sensitivity compared to standard avidin-biotin complexes.

• Counterstaining optimization: Adjust hematoxylin counterstaining time to provide adequate nuclear visualization without obscuring CRADD immunoreactivity.

CRADD antibodies have been successfully applied in human kidney tissue samples , but researchers should validate antibody performance in their specific tissue of interest. When examining tissues, note that CRADD expression has been documented in various human tissues and pathological conditions, including brain diseases, squamous cell carcinoma, inflammation, and kidney diseases .

What is the emerging role of CRADD in vascular biology research?

Recent research has revealed an unexpected role for CRADD in vascular biology, particularly in maintaining endothelial barrier function. Studies employing CRADD-deficient mice and isolated microvascular endothelial cells have demonstrated that CRADD plays a protective role in maintaining the permeability barrier of primary lung microvascular endothelial cells (LMEC) . This represents a significant expansion of our understanding of CRADD beyond its canonical role in apoptotic signaling.

The identification of a novel anti-inflammatory CRADD-BCL10 axis suggests that CRADD may serve as a molecular switch between inflammatory and homeostatic endothelial phenotypes . This finding has important implications for research in vascular inflammation, particularly in contexts such as acute respiratory distress syndrome, sepsis, and other conditions characterized by vascular leak.

Future research directions should focus on:

• Elucidating the molecular mechanisms by which CRADD maintains endothelial barrier integrity

• Investigating potential therapeutic applications targeting the CRADD-BCL10 axis in inflammatory vascular diseases

• Developing more specific tools to study CRADD function in vascular contexts, including endothelial-specific conditional knockout models and high-affinity antibodies for in vivo imaging

These emerging roles for CRADD suggest that this protein may be a valuable target for both basic research into vascular biology and translational research addressing inflammatory vascular pathologies .

How are computational antibody design approaches advancing CRADD antibody research?

Computational antibody design represents a frontier in advancing CRADD antibody research. The RosettaAntibodyDesign (RAbD) framework exemplifies how computational approaches can systematically optimize antibody structures for enhanced targeting of proteins like CRADD. This framework employs a structural-bioinformatics-based computational methodology that samples the diverse sequence, structure, and binding space of antibodies to antigens .

Key advancements in this field include:

• CDR grafting optimization: RAbD samples antibody sequences and structures by grafting structures from canonical clusters of CDRs, then performs sequence design according to amino acid profiles of each cluster . This approach could be applied to optimize existing CRADD antibodies.

• Energy-based optimization strategies: Two primary strategies have shown success in computational antibody design: optimizing total Rosetta energy and optimizing interface energy alone . When applied to CRADD antibodies, these approaches could enhance binding affinity and specificity.

• Quantitative success metrics: Novel metrics including the Design Risk Ratio (DRR) and Antigen Risk Ratio (ARR) provide quantitative measures of computational design success . For non-H3 CDRs, DRRs between 2.4 and 4.0 have been achieved, indicating significant enrichment of native-like features.

• Experimental validation: Computational antibody design approaches have demonstrably improved antibody affinities 10 to 50 fold through CDR replacement . Similar strategies could enhance existing CRADD antibodies or develop novel reagents with improved properties.

As these computational approaches continue to advance, researchers should consider incorporating these methods into CRADD antibody development workflows, particularly when specificity or affinity improvements are required for challenging applications.